Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.61 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.60 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.50 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.48 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92071 | 0.98 | ALDH1A1 (0.95) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL28683526 | 0.95 | ALDH1A1 (0.91) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL15938210 | 0.86 | ALDH1A1 (0.76) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| Aniline SCHEMBL22169118 | 0.86 | ALDH1A1 (0.75) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL19692591 | 0.86 | ALDH1A1 (0.75) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL10818801 | 0.85 | ALDH1A1 (0.72) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL24187387 | 0.84 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL30839723 | 0.83 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL30839719 | 0.83 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL30839720 | 0.83 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2AMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1800185-A | Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes. | BIOVITRUM AB (SE) | 2006-07-12 | — | — | CN | claimed |
| CN-1522245-A | Substituted sulfonamide compounds, process for their preparation and their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-08-18 | — | — | CN | claimed |
| US-8796316-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2014-08-05 | — | — | US | disclosed |
| US-20130274298-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ (BR) | 2013-10-17 | — | — | US | disclosed |
| US-8436027-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2013-05-07 | — | — | US | disclosed |
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ - FIOCRUZ (BR) | 2011-11-03 | — | — | US | disclosed |
| CN-101402601-A | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes | BIOVITRUM AB PUBL (SE) | 2009-04-08 | — | — | CN | disclosed |
| US-20090054501-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | BOECHAT NUBIA | 2009-02-26 | — | — | US | disclosed |
| CN-100457726-C | Substituted sulfonamide compounds, process for their preparation and their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes | CAMBRIDGE BIOTECHNOLOGY LTD (SE) | 2009-02-04 | — | — | CN | disclosed |
| EP-1976832-A2 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | Fundacao Oswaldo Cruz - Fiocruz (BR) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007019660-A2 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | Fundação Oswaldo Cruz - FIOCRUZ (BR) | 2007-02-22 | — | — | WO | disclosed |
| CN-1800185-A | Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes. | BIOVITRUM AB (SE) | 2006-07-12 | — | — | CN | disclosed |
| CN-1522245-A | Substituted sulfonamide compounds, process for their preparation and their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-08-18 | — | — | CN | disclosed |
| US-6737517-B2 | AZO GROUP CONTAINING TRANSITION METAL COMPLEX DYE EXHIBITS A GOOD ACHROMATICITY AS WELL AS A GOOD LIGHT-RESISTANCE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-05-18 | — | — | US | disclosed |
| US-20030149251-A1 | Metal chelated azo dyestuff for inkjet recording and recording liquid for inkjet and inkjet recording method using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-08-07 | — | — | US | disclosed |
| EP-1260556-A1 | METAL CHELATE AZO DYE FOR INK-JET RECORDING, INK-JET RECORDING FLUID CONTAINING THE SAME, AND METHOD OF INK-JET RECORDING | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274298-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CYP51A1, IPO5, TBC1D5 | GAA 64/4885CA2 984/4885ADRA1A 2307/4885 |
| US-20090054501-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CBR3, NOX3, NR2C2 | GAA 3120/4885CA2 2450/4885ADRA1A 1171/4885 |
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CBR3, NOX3, NR2C2 | GAA 3013/4885CA2 2416/4885ADRA1A 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.